Review Article

Association between Sleep Apnea Hypopnea Syndrome and the Risk of Atrial Fibrillation: A Meta-Analysis of Cohort Study

Enfa Zhao,1 Shimin Chen,2 Yajuan Du,1 and Yushun Zhang1

1Department of Structural Heart Disease, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
2Department of Gastroenterology, The First Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

Correspondence should be addressed to Yushun Zhang; zys2889@163.com

Received 31 August 2017; Revised 4 December 2017; Accepted 24 December 2017; Published 18 January 2018

Academic Editor: Ahmed Abdel-Latif

Copyright © 2018 Enfa Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Numerous reports have been done to seek the relationship between sleep apnea hypopnea syndrome (SAHS) and the risk of atrial fibrillation (AF). However, definite conclusion has not yet been fully established. We examined whether SAHS increases AF incidence in common population and summarized all existing studies in a meta-analysis. We summarized the current studies by searching related database for potential papers of the association between SAHS and the risk of AF. Studies that reported original data or relative risks (RRs) with 95% confidence intervals (CIs) for the associations were included. Sensitivity analyses were performed by omitting each study iteratively and publication bias was detected by Begg’s tests. Eight eligible studies met the inclusion criteria. Fixed-effect meta-analysis showed that SAHS increased AF risk in the common population (RR = 1.70, 95% CI: 1.53–1.89, \( P = 0.002 \), \( I^2 = 69.2\% \)). There was a significant association between mild SAHS and the risk of AF (RR = 1.52, 95% CI: 1.28–1.79, \( P = 0.01 \), \( I^2 = 78.4\% \)), moderate SAHS (RR = 1.88, 95% CI: 1.55–2.27, \( P = 0.017 \), \( I^2 = 75.6\% \)), and severe SAHS (RR = 2.16, 95% CI: 1.78–2.62, \( P < 0.001 \), \( I^2 = 91.0\% \)). The results suggest that sleep apnea hypopnea syndrome could increase the risk of AF, and the higher the severity of SAHS, the higher risk of atrial fibrillation.

1. Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice, affecting approximately 1% to 4% of the general population [1]. AF is associated with marked morbidity and increased mortality [1, 2]. It is reported that AF has also been associated with several disease processes such as hypertension, diabetes mellitus, heart failure, myocardial infarction, and valvular heart disease [3]. In recent years, there has been a growing interest about the link between sleep apnea hypopnea syndrome and atrial fibrillation (AF) [4]. Sleep apnea hypopnea syndrome (SAHS) is characterized by recurrent partial or complete collapse of upper airway during sleep and is estimated to affect approximately 5% of adult women and 14% of men [5]. It is reported that SAHS is common in the general population, especially among patients with established cardiovascular disease, including obesity, sedentary life, and increasing age [6]. Several studies have reported a higher prevalence of AF in patients with sleep apnea as compared with those without SAHS [7–9]. However, the conclusions of several observational studies are inconsistent with regard to AF risk. Six studies [3, 10–14] confirmed the link between SAHS and AF, while two studies [15, 16] failed to show any significant association between SAHS and AF.

Therefore, this study aims to conduct a meta-analysis by combining the results from all available cohort studies to examine whether SAHS increases AF incidence in common population and evaluate the risk of AF for mild SAHS (obstructive apnea hypopnea index, 5%–14.9%), moderate SAHS (obstructive apnea hypopnea index, 15%–29.9%), and severe SAHS (obstructive apnea hypopnea index, ≥30), respectively.

2. Materials and Methods

2.1. Literature Search. The meta-analysis was performed based on the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines [17]. Two investigators independently performed a systematic literature search
in any language on July 1, 2017, in EMBASE, PubMed, the Cochrane Library, and the Web of Science without limiting the publication date range. We used the following terms to identify relevant citations: (sleep apnea hypopnea syndromes or sleep apnea syndromes or sleep-disordered breathing or obstructive sleep apnea or obstructive sleep apnea hypopnea syndrome or central sleep apnea or central sleep apnea syndromes or mixed sleep apnea or obstructive apnea hypopnea index or SAHS or OSA or OAHI) and (atrial fibrillation or AF). We also reviewed the reference lists of identified articles to search additional eligible studies. The detailed procedures for the literature search are shown in Figure 1.

2.2. Inclusion and Exclusion Criteria. The following inclusive selection criteria were applied: (1) the study design was based on retrospective or perspective cohort studies; (2) the study evaluated the association between sleep apnea hypopnea syndrome and the risk of atrial fibrillation; (3) a study reporting AF number in SAHS group and AF number in the control group or the relative risks (RRs) with 95% confidence intervals (95% CIs) was included; (4) one of the end points of interest were incident HF; (5) study must contain reference group. Only studies that provided a percentage of the incidence of AF or did not provide available data to allow calculation of the effect estimates were excluded.

2.3. Data Extraction. The following information was recorded by two authors independently for each study using a standardized form: first author, country in which the study was performed, year of publication, study design, follow-up duration, number in case and control groups, and SAHS diagnostic methods. Two investigators independently performed a quality assessment using the 9-star Newcastle-Ottawa Scale (NOS) [18], and the NOS score was verified by a third investigator. We considered papers with NOS scores of 1–3, 4–6, and 7–9 for low, intermediate, and high-quality studies, respectively.

2.4. Statistical Analysis. We performed a meta-analysis to examine the relationship between SAHS and AF risk. Relative risk (RR) with 95% confidence interval (CIs) was used to estimate the effect sizes. A fixed effects model was used to estimate the pooled RR with 95% CIs if there was no significant heterogeneity ($P > 0.05$ and $I^2 < 50\%$); otherwise, a random effect model was used. Heterogeneity was considered as either a $P$ value $< 0.05$ or $I^2 > 25\%$ [19]. Sensitivity analysis was performed by omitting one study at a time to find potential outliers. We used Begg’s test (rank correlation method) [20] to evaluate potential publication bias, and a $P$ value of $<0.1$ was considered as significant.
3. Results

3.1. Characteristics of the Included Studies. Detailed studies retrieval procedures and selection result are shown in Table 1. A total of eight studies [3, 10–16] were included in this meta-analysis, involving 603532 non-SAHS and 14799 SAHS cases. Year of publication ranged from 2007 to 2017. The minimum mean age was 38.9 years and the maximum mean age was 75.0 years. Patients were followed up from 2 years and 4 months to mean 9.2 years. Of the 8 included studies, six were performed in the USA [3, 10, 11, 14–16], one in Australia [13], and one in China [12]. Three of eight studies reported the severity of SAHS [3, 13, 15]. The quality of studies evaluated by the NOS is shown in Table 1. Quality assessment showed that the mean NOS score was 7.25, indicating that the methodological quality was generally good. Table 1 includes the general characteristics of the eligible studies.

3.2. Meta-Analysis Results. Meta-analysis was conducted to ascertain the potential relationship between sleep apnea hypopnea syndrome and the risk of atrial fibrillation among eight studies. As shown in Figure 2, the pooled results indicated that SAHS increased the risk of AF significantly compared to the common population with an increased risk of AF (RR = 1.70, 95% CI: 1.53–1.89) with noticeable heterogeneity ($I^2 = 69.2\%$, $P = 0.002$). We extracted variables that affect research results. Then we further performed meta-analysis to pool the results in studies that adjusted for confounders. After adjustment for the confounders, there was still a positive association between SAHS and the risk of AF with an RR of 1.40 (95% CI: 1.12–1.74, $P < 0.001$).

Three studies reported the severity of SAHS. The obstructive apnea hypopnea (OAHI) was the main index of SAHS severity, defined as the number of obstructive apneas plus hypopneas per hour of sleep. Those with an OAHI of <5% were considered without SAHS (normal). An OAHI of 5%–14.9%, 15%–29.9%, and ≥30 was regarded as mild, moderate, and severe OAHI, respectively, based on clinically accepted cut points [3, 13, 15]. There is a dose-response relationship between SAHS severity and rates of incident AF. The dose-response analysis results (Figure 3) indicated that there was a significant association between mild SAHS and the risk of AF (RR = 1.52, 95% CI: 1.28–1.79, $P = 0.01$, $I^2 = 78.4\%$), moderate SAHS (RR = 1.88, 95% CI: 1.55–2.27, $P = 0.017$, $I^2 = 75.6\%$), and severe SAHS (RR = 2.16, 95% CI: 1.78–2.62, $P < 0.001$, $I^2 = 91.0\%$). The results also suggested that the higher the severity of SAHS, the higher the risk of atrial fibrillation.

3.3. Sensitivity Analysis and Metaregression. Sensitivity analysis was performed by subgroup analyses, which were conducted to handle the clinical heterogeneity across studies according to NOS score and countries. According to the countries where studies were performed, the studies were divided into three subgroups: USA (6 studies), China (one study), and Australia (one study). Meta-analysis of studies performed in USA showed that SAHS was associated with an increased risk of AF (RR = 1.42, 95% CI: 1.25–1.62).
| Author | Year | Country | SAHS Events | Non-SAHS Events | Research type | Age (year) | Follow-up (year) | SAHS diagnosis | Study quality |
|--------|------|---------|--------------|-----------------|---------------|------------|-----------------|----------------|--------------|
| Gamiet al. | 2007 | USA | 114 | 2626 | Retrospective cohort study | 49.0 ± 14.0 | Mean 4.7 years | Polysomnography | 8 |
| Khawaja et al. | 2013 | USA | 81 | 1799 | Prospective cohort studies | 67.7 ± 8.6 | Mean 6.9 ± 2.1 years | Questionnaire | 7 |
| Chao et al. | 2014 | China | 53 | 3970 | Longitudinal cohort study | 38.9 ± 13.1 | Mean 9.2 ± 2.0 years | Polysomnography | 8 |
| Kwon et al. | 2015 | USA | 72 | 707 | Multisite cohort study | 68.4 ± 9.2 | Mean 2 years and 4 months | Polysomnography | 7 |
| Cadby et al. | 2015 | Australia | 374 | 4352 | Consecutive cohort study | 48.3 ± 12.5 | Mean 11.9 years | Polysomnography | 8 |
| Lin et al. | 2015 | USA | 16 | 1408 | Prospective cohort study | 61.3 ± 9.6 | Mean 6.5 ± 0.7 years | Questionnaire | 7 |
| May et al. | 2016 | USA | 4 | 500 | Prospective cohort studies | 75.0 ± 5.0 | Mean 6.5 ± 0.7 years | Polysomnography | 6 |
| Tung et al. | 2017 | USA | 196 | 1440 | Prospective cohort studies | 62.8 ± 11.2 | Average 5.3 years | Polysomnography | 7 |

SAHS: sleep apnea hypopnea syndrome; NOS: Newcastle-Ottawa Scale.
Table 2: Metaregression (inverse variance weights, \( n = 9 \)).

| Var.          | Coeff.     | Std. Err. | \( P \) value | 95% Conf. Interval |
|---------------|------------|-----------|---------------|-------------------|
| Year          | \(-0.0216\) | 0.0402    | 0.61          | \((-0.1200, 0.0767)\) |
| Age           | \(-0.0174\) | 0.0068    | 0.045         | \((-0.0342, -0.0005)\) |
| Gender        | 2.00e – 04 | 0.5342    | 1             | \((-1.3070, 1.3076)\) |
| Sample size   | 2.08e – 07 | 5.20e – 07| 0.702         | \((-1.06e – 06, 1.48e – 06)\) |
| Follow-up duration | 0.0721 | 0.0223    | 0.018         | \((0.017, 0.1269)\) |
| NOS score     | 0.2493     | 0.131     | 0.106         | \((-0.0712, 0.5698)\) |
| SAHS diagnosis| \(-0.1417\) | 0.234     | 0.567         | \((-0.7145, 0.4310)\) |
| Country       | 0.4266     | 0.126     | 0.015         | \((0.1182, 0.7350)\) |

NOS: Newcastle-Ottawa Scale; SAHS: sleep apnea hypopnea syndrome.

Study ID    | RR (95% CI) | Events, SAHS | Events, Non-SAHS | % Weight |
---|-------------|---------------|-------------------|----------|
**Mild**    |             |               |                   |          |
Kwon et al. (2015) | 1.01 (0.60, 1.70) | 26/676 | 28/735 | 5.85          |
Cadby et al. (2015) | 2.06 (1.57, 2.70) | 133/2047 | 81/2570 | 15.67          |
Tung et al. (2017) | 1.28 (1.02, 1.62) | 113/1001 | 142/1614 | 23.72          |
Subtotal \((I^2 = 78.4\%, \text{ } P = 0.010)\) | 1.52 (1.28, 1.79) | 272/3724 | 251/4919 | 45.25          |
**Moderate** |             |               |                   |          |
Kwon et al. (2015) | 1.48 (0.87, 2.54) | 23/407 | 28/735 | 4.35          |
Cadby et al. (2015) | 2.53 (1.90, 3.38) | 96/1202 | 81/2570 | 11.26          |
Tung et al. (2017) | 1.42 (1.05, 1.92) | 51/408 | 142/1614 | 12.50          |
Subtotal \((I^2 = 75.6\%, \text{ } P = 0.017)\) | 1.88 (1.55, 2.27) | 170/2017 | 251/4919 | 28.12          |
**Severe**   |             |               |                   |          |
Kwon et al. (2015) | 0.83 (0.48, 1.42) | 23/730 | 28/735 | 6.09          |
Cadby et al. (2015) | 3.11 (2.39, 4.06) | 145/1477 | 81/2570 | 12.90          |
Tung et al. (2017) | 1.60 (1.12, 2.29) | 32/227 | 142/1614 | 7.64          |
Subtotal \((I^2 = 91.0\%, \text{ } P = 0.000)\) | 2.16 (1.78, 2.62) | 200/2434 | 251/4919 | 26.63          |
Overall \((I^2 = 82.9\%, \text{ } P = 0.000)\) | 1.79 (1.61, 1.99) | 642/8175 | 753/14757 | 100.00          |

**Figure 3:** Dose-response relationships between sleep apnea hypopnea syndrome severity and atrial fibrillation risk in three studies.

without heterogeneity \((I^2 = 0, \text{ } P = 0.522)\). According to the NOS score of each study, the studies were divided into three subgroups. Three studies had scored NOS of 8, four studies scored NOS of 7, and one study scored NOS of 6. Meta-analysis of studies with NOS score of 8 showed that AF risk increased due to SAHS \((RR = 2.17, 95\% \text{ CI } = 1.77–2.67, I^2 = 28.4\%, \text{ } P = 0.247)\). Studies with NOS score of 7 yielded an RR of 1.35 \((95\% \text{ CI } = 1.17–1.55, I^2 = 0, \text{ } P = 0.999)\). Since noticeable heterogeneity was found to be present, metaregression analysis was performed to explore potential sources of heterogeneity. Out of all of the parameters, patients’ age, follow-up duration, and countries where studies were performed were significant sources of heterogeneity \((P = 0.045, 0.018, \text{ and } 0.015, \text{ resp.})\). None of the publication year, gender, sample size, NOS score, and SAHS diagnosis was source of heterogeneity \((P > 0.05)\). The metaregression analysis results are shown in Table 2.

3.4. Publication Bias. To assess bias across studies, Begg’s test with funnel plot asymmetry was used to identify small study effects for the association between SAHS and the risk of AF. We were unable to detect the presence of publication bias in the analyses \((P = 0.833)\), indicating a low probability of publication bias (Figure 4).
syndrome and atrial fibrillation remain unclear, as the two precipitate electrical and structural changes. The exact mechanism hypoxia, hypercapnia, and intrathoracic pressure swing, studies that the physiologic changes of sleep apnea, includ- ing limited. The number of subjects in this study was relatively small and population (32% versus 29%, of obstructive sleep apnea in AF patients and common A case-control study failed to confirm the prevalence severe SAHS increased AF risk 5.66-fold [9]. Not all studies, relationship was found between the risk for AF and severe SAHS [7]. On the other hand, another study found that the risk of AF with OR of 4.02 after adjustment for sex, age, BMI, and coronary heart disease. No dose-response relationship was found between the risk for AF and severe SAHS [7]. On the other hand, another study found that the risk of AF was linearly associated with severity of SAHS; mild SAHS increased AF risk 2.47-fold, and moderate to severe SAHS increased AF risk 5.66-fold [9]. Not all studies, however, have shown a positive association between SAHS and AF. A case-control study failed to confirm the prevalence of obstructive sleep apnea in AF patients and common population (32% versus 29%, \( P = 0.67 \)) [23]. However, the number of subjects in this study was relatively small and the statistical power to detect an association was therefore limited.

There is emerging evidence from animal and human studies that the physiologic changes of sleep apnea, including hypoxia, hypercapnia, and intrathoracic pressure swing, precipitate electrical and structural changes. The exact mechanisms for the association between sleep apnea hypopnea syndrome and atrial fibrillation remain unclear, as the two conditions share many of the same risk factors; however, emerging evidence from animal and human studies indicated that the physiologic changes of sleep apnea including hypoxia, hypercapnia, and activation of sympathetic nervous function may be involved in this process [24]. On the other hand, AF usually reduces cardiac output, which leads to central apnea during sleep, mainly because of the chemoreflex enhancement and prolonged lag to ventilatory response [25]. Previous study reported that obstructive events during sleep promote reductions in the intrathoracic pressure, intermittent hypoxia, and sleep fragmentation [26], which may result in structural cardiac changes, including atrial enlargement and fibrosis [27]. Chronic atrial dilation caused by changes in intrathoracic pressure and surges in blood pressure may facilitate atrial remodeling in SAHS. Besides, SAHS has been reported to increase aorta stiffness that in turn resulted in increased heart afterload and atrial and ventricular remodel- ing [28, 29]. The increased risk of recurrence of AF has been also reported in patients who performed catheter ablation [30]. Another observational study showed that patients with untreated SAHS have a higher recurrence of AF after catheter ablation. Continuous positive airway pressure treatment was associated with a lower recurrence of AF [31]. SAHS induces repeated episodes of hypoxia which trigger chemoreflex and enhance sympathetic nerve activity, leading to tachycardia and blood pressure elevation. The above changes result in repeated myocardial and subsequently atrial ischemia during sleep, thereby promoting AF [32]. Autonomic nervous system dysfunction may be one of the mechanisms by which SAHS increases the incidence of atrial fibrillation [33]. Collapse of upper airway in patients with OSA may result in increased intrathoracic negative pressure. Upper airway collapse in patients with OSA may cause increased chest negative pressure. Sleep-breathing events can also lead to intermittent apnea, hypoxemia, hypercapnia, and other changes in blood gas, as well as sympathetic activation and subsequent hemodynamic changes, which all contribute to the development of atrial fibrillation [34].

In this meta-analysis, we confirmed that sleep apnea hypopnea syndrome could increase the risk of atrial fibrillation. However, our meta-analysis also has limitations. Although we perform a metaregression analysis to evaluate the influence of variables such as history of cardiovascular disease and BMI on the risk of atrial fibrillation, there was significant heterogeneity among dose-response and subgroup studies; we failed to conduct metaregression analysis in these studies because these variables were always unavailable.

In conclusion, our results indicated that sleep apnea hypopnea syndrome could increase the risk of atrial fibrillation. There is a dose-response relationship between sleep apnea hypopnea syndrome severity and rates of incident atrial fibrillation, and the higher the severity of sleep apnea hypopnea syndrome, the higher the risk of atrial fibrillation.

Conflicts of Interest

The authors have declared that no conflicts of interest exist.
Authors’ Contributions

Enfa Zhao and Yushun Zhang designed this study; Shimin Chen and Yajuan Du collected and collated case data; Enfa Zhao and Yajuan Du extracted and confirmed the data; Enfa Zhao and Shimin Chen analyzed data; Enfa Zhao and Shimin Chen wrote the manuscript; Yushun Zhang edited the manuscript. Enfa Zhao and Shimin Chen contributed equally to this work and should be considered co-first authors.

References

[1] F. Rahman, G. F. Kwan, and E. J. Benjamin, “Global epidemiology of atrial fibrillation,” Nature Reviews Cardiology, vol. 11, no. 11, pp. 639–654, 2014.
[2] R. T. Greenlee and H. Vidaillet, “Recent progress in the epidemiology of atrial fibrillation,” Curr Opin Cardiol, vol. 20, no. 1, p. 14, 2005.
[3] P. Tung, Y. S. Levitzky, R. Wang et al., “Obstructive and central sleep apnea and the risk of incident atrial fibrillation in a community cohort of men and women,” Journal of the American Heart Association, vol. 6, no. 7, p. e004500, 2017.
[4] C. T. January, L. S. Wann, J. S. Alpert et al., “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society,” Circulation, vol. 130, no. 23, pp. 2246–2280, 2014.
[5] P. E. Peppard, T. Young, J. H. Barnet, M. Palta, E. W. Hagen, and K. M. Hla, “Increased prevalence of sleep-disordered breathing in adults,” American Journal of Epidemiology, vol. 177, no. 9, pp. 1006–1014, 2013.
[6] P. P. Genta, L. F. Drager, and G. Lorenzi Filho, “Screening for obstructive sleep apnea in patients with atrial fibrillation,” Sleep Medicine Clinics, vol. 12, no. 1, pp. 99–105, 2017.
[7] R. Mehra, E. J. Benjamin, E. Shahar et al., “Association of nocturnal arrhythmias with sleep-disordered breathing: the sleep heart health study,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 8, pp. 910–916, 2006.
[8] T. Mooe, S. Gullbsy, T. Rabben, and P. Eriksson, “Sleep-disordered breathing: A novel predictor of atrial fibrillation after coronary artery bypass surgery,” Coronary Artery Disease, vol. 7, no. 6, pp. 475–478, 1996.
[9] T. Tanigawa, K. Yamagishi, S. Sakurai et al., “Arterial oxygen desaturation during sleep and atrial fibrillation,” Heart, vol. 92, no. 12, pp. 1854–1855, 2006.
[10] A. S. Gami, D. O. Hodge, R. M. Herges et al., “Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation,” Journal of the American College of Cardiology, vol. 49, no. 5, pp. 565–571, 2007.
[11] O. Khawaja, A. Sarwar, C. M. Albert, J. M. Gaziano, and L. Djoussé, “Sleep duration and risk of atrial fibrillation (from the Physicians’ Health Study),” American Journal of Cardiology, vol. 113, no. 4, pp. 547–551, 2013.
[12] T.-F. Chao, K.-L. Wang, Y.-J. Lin et al., “Incidence and risk of atrial fibrillation in sleep-disordered breathing without coexistent systemic disease – Nationwide longitudinal cohort study –,” Circulation Journal, vol. 78, no. 9, pp. 2182–2187, 2014.
[13] G. Cadby, N. McArdle, T. Briffa et al., “Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort,” CHEST, vol. 148, no. 4, pp. 945–952, 2015.
[14] G.-M. Lin, L. A. Colangelo, D. M. Lloyd-Jones et al., “Association of sleep apnea and snoring with incident atrial fibrillation in the multi-ethnic study of atherosclerosis,” American Journal of Epidemiology, vol. 182, no. 1, pp. 49–57, 2015.
[15] Y. Kwon, S. A. Gharib, M. L. Biggs et al., “Association of sleep characteristics with atrial fibrillation: The multi-ethnic study of atherosclerosis,” Thorax, vol. 70, no. 9, pp. 873–879, 2015.
[16] A. M. May, T. Blackwell, P. H. Stone et al., “Central sleep-disordered breathing predicts incident atrial fibrillation in older men,” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 7, pp. 783–791, 2016.
[17] D. Moher, L. Shamseer, and M. Clarke, “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” Systematic Reviews, vol. 4, no. 1, article 1, 2015.
[18] A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010.
[19] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.
[20] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.
[21] D. R. Van Wagoner, J. P. Piccini, C. M. Albert et al., “Progress toward the prevention and treatment of atrial fibrillation: a summary of the heart rhythm society research forum on the treatment and prevention of atrial fibrillation,” Heart Rhythm, vol. 12, no. 1, pp. e5–e29, December 2013.
[22] E. J. Benjamin, P.-S. Chen, D. E. Bild et al., “Prevention of atrial fibrillation. Report from a national heart, lung, and blood institute workshop,” Circulation, vol. 119, no. 4, pp. 606–618, 2009.
[23] K. M. Porthan, J. H. Melin, J. T. Kupila, K. K. K. Venho, and M. M. Partinen, “Prevalence of sleep apnea syndrome in lone atrial fibrillation: A case-control study,” CHEST, vol. 125, no. 3, pp. 879–885, 2004.
[24] P. Tung and E. Anter, “Atrial fibrillation and sleep apnea: Considerations for a dual epidemic,” Journal of Atrial Fibrillation, vol. 8, no. 6, pp. 84–90, 2016.
[25] D. P. Francis, K. Willson, L. C. Davies, A. J. S. Coats, and M. Piepoli, “Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications,” Circulation, vol. 102, no. 18, pp. 2214–2221, 2000.
[26] L. F. Drager, S. M. Tegeiro, V. Y. Polotsky, and G. Lorenzi-Filho, “Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome,” Journal of the American College of Cardiology, vol. 62, no. 7, pp. 569–576, 2013.
[27] D. Linz, B. Linz, M. Hohi, and M. Böhmb, “Atrial arrhythmogenesis in obstructive sleep apnea: Therapeutic implications,” Sleep Medicine Reviews, vol. 26, pp. 87–94, 2016.
[28] L. F. Drager, L. A. Bortolotto, R. P. Pedrosa, E. M. Krieger, and G. Lorenzi-Filho, “Obstructive sleep apnea, hypertension, and their interaction on arterial stiffness and heart remodeling,” CHEST, vol. 131, no. 5, pp. 1379–1386, 2007.
[30] L. Li, Z.-W. Wang, J. Li et al., “Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: A meta-analysis of observational studies,” Europace, vol. 16, no. 9, pp. 1309–1314, 2014.

[31] Y. Naruse, H. Tada, M. Satoh et al., “Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy,” Heart Rhythm, vol. 10, no. 3, pp. 331–337, 2013.

[32] C. A. Goudis and D. G. Ketikoglou, “Obstructive sleep and atrial fibrillation: Pathophysiological mechanisms and therapeutic implications,” International Journal of Cardiology, vol. 230, pp. 293–300, 2017.

[33] J. Sahadevan and D. Srinivasan, “Treatment of obstructive sleep apnea in patients with cardiac arrhythmias,” Current Treatment Options in Cardiovascular Medicine, vol. 14, no. 5, pp. 520–528, 2012.

[34] D. Linz, F. Mahfoud, B. Linz et al., “Effect of obstructive respiratory events on blood pressure and renal perfusion in a pig model for sleep apnea,” American Journal of Hypertension, vol. 27, no. 10, pp. 1293–1300, 2014.
